Andere Sprachen Immunome, Inc.

Aktien

A2QD9D

US45257U1088

IMNM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 11.06.2024			% 5 Tage	% 1. Jan.
15,7 ^USD	-2,18 %		+7,61 %	+46,73 %

31.05.	IMMUNOME, INC. : Piper Sandler behält die Bewertung Kaufen bei	ZM
21.05.	Immunome Insider kaufte Aktien im Wert von $1.388.072, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing	21.05.
Immunome Completes Purchase of Antibodies From Atreca	20.05.
Immunome Promotes Max Rosett to Chief Financial Officer	20.05.
Immunome Announces Completion of Purchase of Assets from Atreca	20.05.
Immunome, Inc. completed the acquisition of Substantially all Assets of Atreca, Inc..	20.05.
Immunome Appoints Max Rosett as CFO	17.05.
Immunome Announces Promotion of Max Rosett to Chief Financial Officer	17.05.
Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer	17.05.
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update	14.05.
Immunome, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	14.05.
Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	14.05.
Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	14.05.
Immunome to Present at 2024 Bank of America Healthcare Conference	08.05.
Immunome Appoints Kinney Horn as Chief Business Officer	02.05.
Immunome, Inc. Appoints Kinney Horn as Chief Business Officer	02.05.
Immunome, Inc. Announces Executive Changes	30.04.
Immunome Appoints Sandra M. Swain to Board of Directors	25.04.
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	25.04.
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting	08.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immunome, Inc.

Aktien

A2QD9D

US45257U1088

IMNM

Andere Sprachen

Filter